Spruce Biosciences downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Spruce Biosciences (SPRB) to Perform from Outperform without a price target The company announced disappointing topline results from both of its ongoing trials of tildacerfont, the analyst tells investors in a research note. The firm awaits clarity on next steps with Spruce winding down both trials and prioritizing cash conservation as it evaluates strategic alternatives.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue